Gaboxadol - Ovid Therapeutics

Drug Profile

Gaboxadol - Ovid Therapeutics

Alternative Names: LU-02030; LU-2-030; MK-0928; OV-101; THIP

Latest Information Update: 22 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Anaesthetics; Analgesics; Anorectics; Antidepressants; Antiepileptic drugs; Hypnosedatives; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome; Fragile X syndrome
  • Preclinical Epilepsy
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 06 Aug 2018 Ovid Therapeutics completes the phase II STARS trial in Angelman Syndrome in USA and Israel (PO) (NCT02996305)
  • 06 Aug 2018 Ovid Therapeutics plans ELARA, an open-label extension trial for Angelman syndrome (Treatment-experienced) in Q4 of 2018
  • 06 Aug 2018 Top-line safety and efficacy results from the phase II STARS trial in Angelman Syndrome released by Ovid Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top